ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

ATACAND
CHF and arrhythmias
Hypertension
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

ATACAND Rx

Generic Name and Formulations:
Candesartan cilexetil 4mg, 8mg, 16mg, 32mg; scored tabs.

Company:
AstraZeneca Pharmaceuticals

Therapeutic Use:

Indications for ATACAND:

Heart failure (NYHA class II-IV and ejection fraction ≤40%), to reduce risk of death and hospitalization; alone or with an ACE inhibitor.

Adult:

≥18yrs: Initially 4mg once daily; double daily dose at 2-week intervals as tolerated to target 32mg once daily. Salt/volume depleted or moderate hepatic impairment: consider lower initial dose.

Children:

<18yrs: not recommended.

Contraindications:

Concomitant aliskiren in patients with diabetes.

Warnings/Precautions:

Fetal toxicity may develop; discontinue if pregnancy is detected. Correct hypovolemia before starting or monitor closely. Monitor BP, renal function, serum K+ periodically. Hepatic or renal impairment. Severe CHF. Renal artery stenosis. Surgery. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.

Interactions:

See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes. Avoid aliskiren in renal impairment (CrCl <60mL/min). Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors. Monitor lithium levels.

Pharmacological Class:

Angiotensin II receptor blocker (ARB).

Adverse Reactions:

Headache, dizziness, hypotension, renal dysfunction, hyperkalemia, back pain, upper respiratory tract infection, pharyngitis, rhinitis, rhabdomyolysis (rare).

How Supplied:

Tabs 4mg, 8mg—30; 16mg, 32mg—30, 90

Indications for ATACAND:

Hypertension.

Adult:

Individualize. ≥18yrs: Monotherapy and not volume-depleted: initially 16mg once daily; usual range: 8–32mg per day once daily or in 2 divided doses. Moderate hepatic impairment: initially 8mg once daily. Salt/volume depleted: consider lower initial dose. May add diuretic if needed.

Children:

<1yr or CrCl<30mL/min: not recommended. Give once daily or in 2 divided doses. 1–<6yrs (may give oral susp if unable to swallow tabs): initially 0.2mg/kg/day; usual range: 0.05–0.4mg/kg/day. 6–<17yrs (<50kg): initially 4–8mg/day; usual range: 2–16mg/day; (>50kg): initially 8–16mg/day; usual range: 4–32mg/day. Salt/volume depleted: consider lower initial dose.

Contraindications:

Concomitant aliskiren in patients with diabetes.

Warnings/Precautions:

Fetal toxicity may develop; discontinue if pregnancy is detected. Correct hypovolemia before starting or monitor closely. Monitor BP, renal function, serum K+ periodically. Hepatic or renal impairment. Severe CHF. Renal artery stenosis. Surgery. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.

Interactions:

See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes. Avoid aliskiren in renal impairment (CrCl <60mL/min). Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors. Monitor lithium levels.

Pharmacological Class:

Angiotensin II receptor blocker (ARB).

Adverse Reactions:

Headache, dizziness, hypotension, renal dysfunction, hyperkalemia, back pain, upper respiratory tract infection, pharyngitis, rhinitis, rhabdomyolysis (rare).

How Supplied:

Tabs 4mg, 8mg—30; 16mg, 32mg—30, 90

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs